Captopril as a Potential Inhibitor of Lung Tumor Growth and Metastasis

  title={Captopril as a Potential Inhibitor of Lung Tumor Growth and Metastasis},
  author={Samir Attoub and A M Gaben and Suhail Al-Salam and Mahmood Ahmed Al Sultan and Anne John and Michael Gary Nicholls and J{\'a}n Mester and Georg A. Petroianu},
  journal={Annals of the New York Academy of Sciences},
Lung cancer is the most common form of cancer in the world, and 90% of patients die from their disease. The angiotensin converting enzyme (ACE) inhibitors are used widely as antihypertensive agents, and it has been suggested that they decrease the risk of some cancers, although available data are conflicting. Accordingly, we investigated the anticancer activity of the ACE inhibitor, captopril, in athymic mice injected with highly tumorigenic LNM35 human lung cells as xenografts. Using this… 

Zofenopril antitumor activity in mice bearing Ehrlich solid carcinoma: Modulation of PI3K/AKT signaling pathway

This study has provided novel insights into the possible mechanisms by which ZF may produce its tumor defeating properties and elucidating the involved trajectories involve the interference between PI3K/Akt and CBS signaling pathways.


The findings suggest that blockade of RAS decreases the tumor proliferation capacity and metastatic potential of renal cell carcinoma in this experimental model.

Anti-cancer Potential of Captopril and Botulinum Toxin Type-A and Associated p53 Gene Apototic Stimulating Activity

  • R. Shebl
  • Biology, Medicine
    Iranian journal of pharmaceutical research : IJPR
  • 2019
BTX-A and captopril could present potential anti-cancer candidates through triggering cancer cells towards self-destruction through triggers of apoptosis, and both drugs showed inhibitory potentials on cellular proliferation and the ability of cancer cells to migrate in scratched monolayers was obviously inhibited.

Tumor growth-inhibitory effect of an angiotensin-converting enzyme inhibitor (captopril) in a lung cancer xenograft model analyzed using 18F-FDG-PET/CT

It was found thatcaptopril exerted a potential tumor growth-inhibitory effect; this was because the captopril-administrated group showed low values of MTV, maximum standardized uptake value, total lesion glycolysis, and tumor volume in comparison with the control group.

Overexpression of ACE2 produces antitumor effects via inhibition of angiogenesis and tumor cell invasion in vivo and in vitro.

The results suggest that the overexpression of ACE2 may potentially suppress the invasion and angiogenesis of NSCLC.

The angiotensin-converting enzyme 2 in tumor growth and tumor-associated angiogenesis in non-small cell lung cancer.

It is shown for the first time that ACE2 expression decreased in NSCLC tissue in which AngII was higher than the matching non-malignant tissues and overexpression of ACE2 may have a protective effect by inhibiting cell growth and VEGFa production in vitro.

The Therapeutic Potential of Angiotensin-converting Enzyme and Angiotensin Receptor Inhibitors in the Treatment of Colorectal Cancer: Rational Strategies and Recent Progress.

The application of anti-hypertensive medications such as losartan might have a therapeutic impact, although further preclinical and clinical studies might provide novel insight into the potentially beneficial effect of ACE-Is in the treatment of colorectal cancer patients.

Inhibition of Angiotensin II Type I Pathway Reduced Tumor Growth and Ameliorates Fibrosis/inflammation Associated with Colorectal Cancer

Valsartan may protect cells against intestinal fibrosis by modulation of profibrotic and pro-inflammatory components include fibronectin, Interleukin and Monocyte Chemotactic Protein 1 (MMP1).

The Angiotensin-Converting Enzyme Inhibitory State Promotes the Transformation of Non-Small Cell Lung Cancer Blood Supply Pattern Toward Vasculogenic Mimicry Formation

It is proved that status of tumor blood supply patterns, including VM channels and endothelial vessels, can dynamically exchange with each other along with local RAS fluctuations in microenvironment and induced changes induced by ACE2/ACEI relate to relatively low metastasis rate and comforting prognoses of NSCLC patients.



Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma.

In vitro, captopril at clinically achievable doses (0.1-10 microM) had no significant effect on the incorporation of [3H]thymidine into SN12K-1 cells, and this highly significant attenuation byCaptopril of in vivo tumour growth does not appear to be due to a direct effect onThe proliferation of the tumour cells.

Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats.

This widely used drug is defined as a new inhibitor of neovascularization and the possibility that patients on long term captopril therapy may derive unexpected benefits from its antiangiogenic activities is raised.

Effects of the angiotensin-I converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells

The findings suggest that perindopril has no direct cytotoxicity against tumor cells, but has a potential to inhibit tumor growth due to suppression of VEGF-induced angiogenesis in vivo.

Inhibition of proliferation on some neoplastic cell lines-act of carvedilol and captopril.

Understanding the action of these established and clinically accepted agents could provide a basis for design of improved therapeutic regimens in the treatment of cancer diseases.

Does Captopril Have a Direct Pro-Apoptotic Effect?

The induction of apoptotic phenomena may be a mechanism by which ACE inhibitors affect cardiovascular remodelling and it might also explain the favorable effect these drugs have on diseases such as IgA nephropathy and diabetic nephtropathy.

The novel inhibitor of heterotrimer G-protein signaling, BIM-46174, enhances the anticancer activity of cisplatin in human NSCLC lung tumor xenografts

The data obtained with BIM-46174 establish heterotrimeric G-protein signaling as a new therapeutic target in lung cancer, especially in combination with cisplatin, and this result was previously reported in SCLC.

Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth.

It is shown that host angiotensin II (ATII) type 1 (AT1) receptor plays an important role in angiogenesis and growth of tumor cells engrafted in mice, and the host ATII-AT1 receptor pathway thereby plays important roles in tumor-related angiogenic and growth in vivo.

The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor.

  • H. YoshijiS. Kuriyama H. Fukui
  • Biology, Medicine
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2001
The results showed that the ACE inhibitor perindopril inhibited tumor development and angiogenesis independent from AT(1)-R blockage, and that VEGF alternation may be involved in the mechanism of this inhibitory effect.

Activation of invasiveness of cervical carcinoma cells by angiotensin II.

Proangiogenic Effect of Angiotensin-Converting Enzyme Inhibition Is Mediated by the Bradykinin B2 Receptor Pathway

Proangiogenic effect of ACE inhibition is mediated by B2-receptor signaling and was associated with upregulation of eNOS content, independently of VEGF expression.